Skip to main content
IMA
NASDAQ Life Sciences

ImageneBio Taps Yanina Grant-Huerta as CFO While CMO Shifts to Consulting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.57
Mkt Cap
$65.781M
52W Low
$3.94
52W High
$213.062
52W Position info
41% above low
Off High info
97% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

IMA sits 41% above its 52-week low of $3.94 on light trading volume (0.2× avg).

Summary

ImageneBio appointed Yanina Grant-Huerta as CFO and announced the transition of its Chief Medical Officer to a consulting role, marking two senior leadership changes in quick succession.


Key Events · Executive and Board Changes · IMA

  • New CFO Appointed

    Effective July 20, 2026, Yanina Grant-Huerta steps in as CFO with a compensation package that includes a $450,000 base salary, a 40% target bonus, 65,000 RSUs, and 95,000 stock options.

  • CMO Transition to Consulting

    Chief Medical Officer Benjamin Porter-Brown will transition to a consulting role effective July 24, 2026, reducing his full-time involvement.

  • Leadership Vacuum Filled

    The appointment fills the principal financial officer role left vacant by the resignation of SVP Robert Lally on June 26, 2026.

  • Resale Shelf Updated

    The prospectus supplement updates the resale registration for 2,508,337 shares, originally filed in May 2026, with the attached 8-K disclosures.


Analysis · IMA · Life Sciences

Filling the vacancy left by the prior finance head's resignation in June, ImageneBio has appointed Yanina Grant-Huerta as CFO. She brings experience from Atara Biotherapeutics and Amgen, and her compensation package includes a $450,000 salary, a 40% bonus target, and equity grants of 65,000 RSUs and 95,000 options. At the same time, Chief Medical Officer Benjamin Porter-Brown will move to a consulting role, scaling back his day-to-day involvement. These back-to-back leadership changes follow a period of significant dilution and a recent $30 million private placement, raising questions about stability and strategic direction.

At the time of this filing, IMA was trading at $5.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $65.8M. The 52-week trading range was $3.94 to $213.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMA - Latest Insights

IMA
Jun 29, 2026, 7:05 AM EDT
Filing Type: 424B3
Importance Score:
8
IMA
Jun 26, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
IMA
Jun 17, 2026, 4:09 PM EDT
Filing Type: 424B3
Importance Score:
7
IMA
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
IMA
May 07, 2026, 5:23 PM EDT
Filing Type: 424B3
Importance Score:
8